Peptide Sciences Just Shut Down: What Florida Med Spas, Clinics, and Compounders Should Do Now

Peptide Sciences, the largest research peptide vendor in the country, posted a three-sentence shutdown notice on March 6, 2026, and went dark. No FDA warning letter on the public docket. No press release. No refund process. The company was reportedly making $7.4 million a month in sales the December before it closed. If you run a Florida med spa, a wellness clinic, a telehealth practice, or a compounding pharmacy that touches peptides, the closure should not surprise you. It should worry you.

I am writing this from the perspective of a federal criminal defense attorney who has handled healthcare fraud, controlled substances, and FDA enforcement cases for more than three decades. The point here is not to tell peptide operators they should panic. It is to explain what the government is actually building, what statutes carry real prison exposure, and what people in this industry tend to do early in an investigation that makes their cases significantly worse.

For peptide operators, the real risk is not rumor. It is a federal case file that may already be forming.

What Actually Happened With Peptide Sciences

Peptide Sciences was the default brand name in the research peptide world. Researchers, biohackers, and an enormous number of clinics and med spas either bought directly or sourced through resellers that did. The company sold compounds like BPC-157, TB-500, retatrutide, tesamorelin, CJC-1295, and various GLP-1 analogs under "research use only" and "not for human consumption" labels.

The shutdown was called voluntary. That word is doing a lot of work. It came after eighteen months of escalating federal activity that included a physical FDA raid on Amino Asylum's Memphis warehouse in June 2025, more than fifty FDA warning letters issued to GLP-1 compounders in September 2025, and a guilty plea by the founders of Paradigm Peptides in December 2025 in the Northern District of Indiana.

In that case, the government found that products labeled as SARMs contained testosterone, a Schedule III controlled substance, and that the peptides, hCG, and SARMs the company sold were all unapproved new drugs under the Federal Food, Drug, and Cosmetic Act.

Why The Shutdown Should Not Surprise Anyone In This Industry

Around the same time, HHS Secretary Robert F. Kennedy Jr. announced on the Joe Rogan Experience podcast that fourteen of the nineteen previously restricted Category 2 peptides would be moved back to Category 1, restoring access through licensed compounding pharmacies with a prescription.

That announcement is being misread inside the industry as a green light. It is not. It is the opposite. The government is telling the market that the legitimate channel is a licensed pharmacy with a prescriber. That same message tells federal prosecutors that the gray market channel is no longer necessary, and therefore harder to defend.

The industry keeps calling these developments mixed signals. They are not mixed. The government is drawing a line between licensed prescribing and gray market peptide sales, then building cases around everyone who stayed on the wrong side of it.

What Federal Prosecutors Are Actually Building

The Peptide Sciences shutdown is a piece of a coordinated enforcement posture. FDA's Office of Criminal Investigations, the DOJ Consumer Protection Branch, the FBI, and in some districts the DEA are all working peptide and unapproved drug cases. The pattern of cases tells you where the government's interest sits.

Prosecutors are focused on a few specific things:

• sellers and clinics moving compounds that the government can credibly call unapproved new drugs being marketed for human use, regardless of the disclaimer on the label
• anything labeled as a peptide or SARM that actually tests positive for a controlled substance like testosterone
• GLP-1 analogs, semaglutide and tirzepatide in particular, where Eli Lilly and Novo Nordisk have built parallel civil litigation that hands the criminal side ready-made evidence
• compounding pharmacies and 503A operations that drift outside the patient-specific prescription model and start looking like manufacturers
• med spas, ketamine clinics, longevity practices, and telehealth platforms that ordered from gray market suppliers and dispensed without a clean prescriber relationship and a real patient encounter

Why Florida Operators Sit In The Crosshairs

Florida has one of the densest concentrations of med spas, IV hydration practices, longevity clinics, ketamine clinics, telehealth operators, and compounding pharmacies in the country. South Florida in particular is a focus for HHS-OIG, FBI Healthcare Fraud, and the U.S. Attorney's Offices in the Southern, Middle, and Northern Districts.

When the federal map of peptide enforcement gets drawn, this state is going to be on it. That matters because many Florida businesses built peptide lines during the 2023 to 2025 boom, often with loose sourcing practices, thin prescriber oversight, and aggressive online marketing.

Florida operators should stop assuming they are too small or too local to matter. Federal healthcare cases often start with online ads, shipping records, payment processor flags, or a supplier who already decided to cooperate.

The Statutes That Carry Real Prison Exposure

Peptide cases are not just regulatory. They sit at the intersection of several federal criminal statutes that frequently get charged together.

The most common charging tools in this space are 21 U.S.C. § 331 and § 333 for FDCA misbranding and adulteration, 21 U.S.C. § 841 if any product turns out to contain a controlled substance, 21 U.S.C. § 846 for conspiracy, 18 U.S.C. § 1341 and § 1343 for mail and wire fraud, 18 U.S.C. § 1956 and § 1957 for money laundering, and 18 U.S.C. § 1347 for healthcare fraud when insurance or other third-party payors enter the chain.

Florida exposure can run in parallel. Chapter 458 creates criminal risk for the unlicensed practice of medicine, and Chapter 499 creates separate state drug and cosmetic act issues, especially when injections happen at facilities without a real medical director.

"The government does not have to prove a peptide was dangerous to charge the case. It has to prove the product was an unapproved new drug being marketed or distributed for human use, or that the product actually contained a controlled substance."

Why Research-Only Labels Do Not Save The Case

The government does not have to prove a peptide is dangerous, contaminated, or counterfeit to charge a case. FDCA prosecutions turn on whether something is an unapproved new drug being marketed or distributed for human use. Disclaimers and "research only" labels do not control the analysis. Marketing language, social media, dosing instructions, and customer base do.

If a product labeled as a peptide or SARM tests positive for testosterone or another controlled substance, the posture gets worse fast. What looked like a regulatory problem becomes a Title 21 controlled substance case with real prison exposure.

The Mistakes Operators Make In The First Forty-Eight Hours

When a peptide vendor, clinic owner, or compounder first realizes the government is looking, the next forty-eight hours often determine the case.

The recurring mistakes are predictable:

• talking to FDA OCI agents or HHS-OIG investigators without counsel
• producing documents to an administrative subpoena without a litigation hold or privilege review
• continuing to operate normally while a target letter is sitting on the desk
• deleting website content, shipping data, emails, or texts after learning of the investigation
• calling suppliers, marketing partners, or prescribers to coordinate a story
• waiting until indictment to retain counsel

Those moves create false statement risk under 18 U.S.C. § 1001, obstruction exposure under 18 U.S.C. § 1519, and fresh overt acts for a future conspiracy count.

What A Real Pre-Indictment Defense Strategy Looks Like

If you are a Florida med spa owner, a clinic operator, a compounding pharmacist, a telehealth platform principal, or a peptide distributor and you have any reason to believe the government is interested, the goal is not to convince yourself the case will not be charged. The goal is to control as many variables as possible while you still can.

Effective early intervention usually includes issuing a litigation hold immediately, stopping any document destruction practices, mapping the conduct against the elements of the likely statutes, identifying who else is talking, cleaning up the prescribing relationship, and engaging directly with the AUSA or line agent through counsel before charging decisions are made.

Some clients should fight. Some should resolve. That decision should be made deliberately, with full understanding of guideline exposure, and not by default.

Why Timing Matters Right Now

The peptide enforcement wave is not slowing down. The reclassification announcement reopened a legitimate compounding channel. The SAFE Drugs Act, introduced in early 2026, would prohibit the sale of research chemicals structurally identical to FDA-approved drugs without a New Drug Application. Pharmaceutical companies are running parallel patent and ITC litigation that produces evidence the government uses. Payment processors are dropping accounts. Banks are filing Suspicious Activity Reports.

Every one of those moving pieces narrows the runway. Cases that were considered borderline in 2024 are being charged in 2026. Conduct that looked routine eighteen months ago is now sitting in agent reports. If you operated as a peptide vendor, a clinic dispenser, a telehealth prescriber, or a 503A compounder during the 2023 to 2025 window, your conduct is potentially under review whether you have heard from the government or not.

The best outcomes in peptide cases usually come before indictment, when the story, the documents, and the charging decision are still in motion.

Under Federal Investigation Over Peptides, GLP-1 Compounds, Or Med Spa Operations?

AMC Defense Law represents physicians, compounding pharmacists, med spa owners, telehealth operators, peptide distributors, and clinic principals in federal healthcare and FDA criminal investigations. Our practice handles unapproved new drug, controlled substance, healthcare fraud, and white collar matters in the Southern, Middle, and Northern Districts of Florida and in federal courts nationwide.

If you have received a target letter, a grand jury subpoena, a § 806 administrative subpoena, an FDA Form 482 inspection notice, or if agents have visited your facility, your home, or a client, contact our office for a confidential consultation. The earlier we are in the case, the more options remain on the table.

If you or your loved ones have been arrested or are under federal investigation, call Aaron M. Cohen, 24 hours a day to get help.